Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)

類似資料

• Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
  著者:: Maniatis, Aristides K, 等
  出版事項: (2021)
• OR10-05 Phase 3 FliGHt Trial: Experience of Switching from Daily Growth Hormone Therapy to Once-Weekly TransCon HGH in Children with Growth Hormone Deficiency
  著者:: Maniatis, Aristides K, 等
  出版事項: (2020)
• SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial
  著者:: Maniatis, Aristides K, 等
  出版事項: (2020)
• A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency
  著者:: Höybye, Charlotte, 等
  出版事項: (2017)
• OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial
  著者:: Thornton, Paul, 等
  出版事項: (2019)